Summary:
In patients with diabetic foot osteomyelitis (DFO), oral N-Acetyl-Cysteine (NAC) 600 mg twice daily as an adjuvant therapy significantly accelerated antibiotic responses and reduction in infectious inflammatory markers compared to standard antibiotic therapy alone, though it was associated with mild gastrointestinal side effects.
| PICO | Description |
|---|---|
| Population | Adults with diabetic foot osteomyelitis (DFO). |
| Intervention | Oral N-Acetyl-Cysteine (600 mg twice daily) as an adjuvant to standard antibiotic therapy. |
| Comparison | Standard antibiotic therapy alone without N-Acetyl-Cysteine. |
| Outcome | Significant acceleration in antibiotic responses and reduction of infectious inflammatory markers in the NAC group. Associated with mild gastrointestinal side effects. |
Source: Laya Hooshmand Gharabagh, et al. “Efficacy Of N-Acetyl-Cysteine as Adjuvant Therapy for Diabetic Foot Osteomyelitis: An Open-Label Randomized Controlled Trial.” Read article here.
